TLC denies rumours of CEO resignation:
This article was originally published in Clinica
Laser surgery services company TLC has denied rumours that its president and CEO, Elias Vamvakas, has already, or intends to resign. Mr Vamvakas is also one the company's largest individual shareholders. The Bethesda, Maryland-based company issued the statement following speculation after recent increased trading in its shares. TLC believes a similar false rumour on the Internet concerning the CEO of one of its competitors may have fuelled the suggestion. No senior management members have resigned, or intend to, and the company is unable to explain the market activity in its shares.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.